![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 42, 30019-30022, October 15, 1999
From the Pharmacogenetics Section, Laboratory of Reproductive and
Developmental Toxicology, NIEHS, National Institutes of Health,
Research Triangle Park, North Carolina 27709
Estrogen sulfotransferase (EST) exhibits a high
substrate specificity and catalytic efficiency toward estrogens such as
estradiol (E2) but insignificant ability to sulfate hydroxysteroids
such as dehydroepiandrosterone (DHEA). To provide the structural basis for this estrogen specificity, we mutated amino acid residues that
constitute the substrate-binding site of EST. Among these mutants, only
Tyr-81 decreased E2 and increased DHEA sulfotransferase activities.
Substitution for Tyr-81 by smaller hydrophobic residues increased
Km(E2) for E2 activity, whereas the
kcat(E2) remained relatively constant. The Y81L
mutant exhibited the same DHEA activity as wild-type hydroxysteroid
sulfotransferase, for which
Km(DHEA) remained
relatively constant, and kcat(DHEA) was
markedly increased. The side chain of Tyr-81 is directed at the A-ring
of the E2 molecule in the substrate-binding pocket of EST, constituting
a steric gate with Phe-142 sandwiching E2 from the opposite side. The
present mutagenesis study indicates that the 3 Steroid hormones are sulfated by enzymes called cytosolic
sulfotransferases that transfer sulfuryl groups to the substrates from
the ubiquitous cofactor 3'-phosphoadenosine 5'-phosphosulfate (PAPS).1 Steroid sulfates are
stored as inactive hormones that can be reactivated by steroid
sulfatases, providing a mechanism for regulating endocrine homeostasis
(1). Thus, as an alternative to aromatase inhibitors, the steroid
sulfation/desulfation system is currently considered as a drug target
for hormone-sensitive diseases such as certain types of breast cancer
(2-5). Steroid sulfotransferases are subgrouped based on their
substrate preferences, estrogen sulfotransferase (EST) and
hydroxysteroid sulfotransferase (HST). Characteristically, EST displays
a far greater specificity and efficiency to sulfate E2 than HST does to
sulfate DHEA. The underlying structural principle for EST to manifest
such high estrogen preferences remains a question of major interest.
In the last 10 years, more than 30 cytosolic sulfotransferase cDNAs
have been cloned from bacteria, plant, and mammals including humans
(6). The amino acid sequence comparisons of these sulfotransferases suggest a conserved sequence motif for the putative PAPS-binding site
(6, 7). An empirical method has been introduced to identify residues
that are involved in catalysis and/or in determining substrate
specificity for sulfotransferases (8, 9). A bacterially expressed EST
that was originally cloned from a mouse testis cDNA library (10)
sulfates preferentially E2 (11). The crystal structures of murine EST
complexed with inactive cofactor 3'-phosphoadenosine 5'-phosphate and
E2 or vanadate have been solved (12, 13). These structures have
revealed the PAPS-binding motif that is conserved in all cytosolic
sulfotransferases. The transition state model mimicked by the
EST-PAP-vanadate structure suggests that sulfotransferase reaction
proceeds in an in-line sulfuryl transfer. This structure-based
mechanism is consistent with a Random Bi Bi mechanism proposed
previously based on enzyme kinetic analyses (14, 15). Moreover, these
structural motifs and reaction mechanisms are also conserved in a group
of Golgi membrane sulfotransferases that sulfate high molecular weight
substrates such as carbohydrates, polysaccharides, and proteins
(16-18). Thus, EST structures have provided an excellent basis to
investigate the underlying principles that determine the substrate
specificity of EST and other sulfotransferases.
For the present study, we have employed the structural information for
EST to select residues for mutagenesis. EST transfers the 5'-sulfate of
PAPS to the phenolic hydroxyl at 3-position of E2. The E2 molecule is
accommodated horizontally in the cylindrical hydrophobic pocket, in
which the hydroxyl group of E2 is inserted deep into the active site,
whereas the 17 Materials--
[1,2,6,7-3H]Dehydroepiandrosterone
(60 Ci/mmol), [2,4,6,7-3H]estradiol (72 Ci/mmol),
[7-3H]pregnenolone (25 Ci/mmol), and
[1,2-3H]androstenediol (42 Ci/mmol) were purchased from
NEN Life Science Products. AD was obtained from Steraloids, and E2,
DHEA, and PREG were obtained from Sigma.
Site-directed Mutagenesis and Bacterial Expression of the Mutated
Enzymes--
Site-directed mutagenesis, expression, and purification
were performed as described previously (13). Briefly, a QuickChange kit
(Stratagene) was used to introduce mutations into EST sequence in
pGEX-4T3 plasmid by polymerase chain reaction, and mutations were
verified by DNA sequencing. Mutated enzymes were expressed as fusion
proteins with glutathione S-transferase, applied on glutathione-Sepharose (Amersham Pharmacia Biotech) and subsequently eluted by thrombin cleavage (Sigma).
Sulfotransferase Assay and Kinetic
Analysis--
Sulfotransferase activity was assayed as described
previously (10). The reaction mixture (200 µl of 100 mM
Tris-HCl buffer, pH 8.0, and 100 µM PAPS) was extracted
with 2 volumes of dichloromethane, and an aliquot of the aqueous phase
was used for scintillation counting. Km and
kcat values were calculated by nonlinear regression analysis using either a constant amount of radioactive substrate (in total concentrations of 3.5, 7.0, 13.9, 17.8, 25.6, 41.3, 72.5, 135, 260, and 510 nM) or constant ratio of labeled to
unlabeled ligand (in total concentrations of 0.25, 0.5, 1.0, 2.0, 4.0, and 8 µM). For cases for which sulfotransferase activity was inhibited by a high concentration of substrate, the data were processed using a model previously published to determine
Km and kcat values (15).
Protein concentration was determined spectrophotometrically using an
A280 nm,1 mg/ml of 1.6 for EST and 2.2 for
HST. Apparent molecular masses of 35,000 and 30,000 were used to
calculate kcat values for EST and HST, respectively.
Substrate-binding Site of EST--
EST binds the hydrophobic
substrate E2 tightly within the van der Waals surface of the
hydrophobic substrate binding pocket (12). Fig.
1 depicts residues constituting the
surface of the substrate pocket. Arg-23, Asn-86, Ser-148, and Met-247
are positioned below the D-ring of the E2 molecule. This group of
residues forms the entrance to the pocket, with the side chain of
Asn-86 hydrogen-bonded to the 17 Screening of Mutants--
Mutated ESTs were expressed, purified,
and their sulfotransferase activities determined using E2 and DHEA as
substrates (Table I). Mutations of
residues on section I affected E2 sulfotransferase activity only
slightly. Even the N86A mutant that abolishes a hydrogen bond of Asn-86
to the 17 Kinetic Analysis of Tyr-81 and Phe-142 Mutants--
Since Y81L was
the only mutant that significantly increased DHEA sulfotransferase
activity, further mutational analysis was conducted with Y81L, Y81F,
and Y81A. First, we determined Km and
kcat values of wild-type EST for E2 and DHEA
sulfotransferase activities (Table II). General
Km(E2) and
kcat(E2) values were on the order of 10 nM and 10 s
In the x-ray crystal structure of EST complexed with E2 and PAP (12),
Phe-142 and Tyr-81 form a narrow channel to the substrate pocket that
sandwiches the E2 molecule. Although the mutation of Phe-142 to Leu did
not increase the DHEA sulfotransferase activity of EST, it decreased
profoundly E2 sulfotransferase activity (Table I). To examine further
the role of Phe-142 in determining the substrate specificity of EST, we
constructed an additional Phe-142 mutant and also a double mutant in
which both Tyr-81 and Phe-142 were mutated simultaneously. F142L
exhibited a 40-fold higher Km(E2) for E2
sulfotransferase activity than wild-type EST, with the same
kcat(E2) value. Both
Km(DHEA) and kcat(DHEA) of F142L for DHEA sulfotransferase activity remained at levels similar to those of wild-type EST. Finally,
we mutated Phe-142 to Ala (F142A) to make the side chain size smaller.
This mutation resulted in a 100-fold decrease of the catalytic power
(Km(E2)/kcat(E2)) of EST to sulfate E2, caused primarily by a marked increase of Km(E2). F142A abolished completely DHEA
sulfotransferase activity. As expected, the F142L/Y81L double mutant
showed little catalytic power for either E2 or DHEA sulfotransferase activity. In the double mutant, the change in Km for E2 sulfotransferase activity was determined by Leu-142, whereas the
alteration of kcat was dictated by Leu-81.
Similarly, Leu-81 and Leu-142 defined the kcat
and Km values for DHEA sulfotransferase activity,
respectively. These observations for the F142L/Y81L mutant are
consistent with the manner in which Km and kcat were defined in the corresponding single mutants.
Androstenediol Sulfotransferase Activity--
One of the main
structural differences of DHEA from E2 is the presence of the C-19
methyl group. We might infer that the presence of the C-19 methyl group
may prevent DHEA from becoming an efficient substrate of EST. For
testing this inference, we used steroid androstenediol (AD), which
contains the C-19 methyl group as a substrate. AD differs from DHEA by
only the hydroxyl group at the C-17 position. As expected, wild-type
EST exhibited little ability to sulfate AD, whereas wild-type HST
sulfated AD efficiently (Table III). The
Y81L mutant of EST exhibited markedly increased AD sulfotransferase
activity, with a 4-fold lower Km and a 5-fold higher
kcat for AD sulfotransferase activity compared with wild-type EST. Based on the
kcat/Km ratio, the Y81L mutation elevated the AD sulfotransferase activity to 30% of the level
observed in wild-type HST. The F142L mutant had virtually no AD
activity; the Km and kcat
values were practically identical to wild-type EST. In addition to AD,
pregnenolone (PREG) was also sulfated by the Y81L mutant but not by the
wild-type and F142L enzymes (data not shown). PREG is another steroid
having the C-19 methyl group. Thus, these results provided further
evidence that EST utilizes steric hindrance by the C-19 methyl group of steroids with Tyr-81 to confer substrate specificity.
General Discussion--
Residues Tyr-81 and Phe-142 form a
stricture-like gate that dictates the binding of steroids in the
substrate pocket of EST. Superposition of DHEA with E2 in the substrate
binding pocket shows that the C-19 methyl group of DHEA molecule is
within 2.29 Å of C-
Tyr-81 appears to be the determining factor in the alteration of the
substrate specificity of EST to DHEA sulfotransferase activity. In the
Tyr-81 mutants, kcat for DHEA sulfotransferase activity was increased markedly compared with wild-type EST. This indicates that the gate can be widened by mutation of Tyr-81, allowing
for EST to accommodate DHEA deep into the substrate pocket near the
catalytic center. The molecule modeled in the EST pocket shows that the
C-19 methyl group makes a clashing contact (2.29 Å) with a carbon atom
(C-
Steric hindrance by a critical residue has been proposed as an
underlying principle that can regulate substrate and/or product specificities of enzymes catalyzing hydrophobic substrates. It is well
known that the sizes of these residues alter the P450 specificities
(Ref. 19 and references therein). For example, mutation of Phe-209 to
Leu converted the substrate specificity of CYP2A5 from coumarin to a
larger molecule, testosterone. Placing a large amino acid Phe at
position 209 appeared to inhibit binding of testosterone to CYP2A5
(20). By taking advantage of the presence of the x-ray crystal
structure, Graham-Lorence et al. (21) demonstrated that
Phe-87 of P450 BM-3 acts through steric hindrance to determine the
regio- and stereospecificity of the arachidonic acid epoxygenase activity; F87V produced the (14S,15R)-epoxide,
whereas wild-type P450 BM-3 the
(17S,18R)-epoxide. Similarly, Met-418 was a
factor for defining the specificity of 15-lipoxygenase activity, and the M418V mutant increased markedly 12-lipoxygenase activity to the
level of 15-lipoxygenase activity (22). G173M in
UDP-N-acylglucosamine acetyltransferase (in E. coli) acts as a hydrocarbon ruler to alter the acyl donor
substrate from (R)-3-hydroxymrystoyl-acyl carrier
protein to (R)-3-hydroxyldecanoyl-acyl carrier
protein (23). Since kinetic parameters were not determined in those studies, it is not possible to discuss details as to how the mutations regulate the substrate and/or product specificities. To our knowledge, the Tyr-81/Phe-142 gate of EST is the first clear example for the
existence of such a gate in a hydrophobic substrate pocket that confers
high substrate specificity.
In conclusion, we have demonstrated that the gate-like structure
regulates EST specificity depending on the chemical properties of the
substrates. The gate provides EST with a high catalytic power to
sulfate E2 by regulating the binding affinity of EST to E2. The gate
can be widened through mutagenesis so as to accommodate DHEA deep into
the catalytic core, altering EST to an enzyme that sulfates DHEA with a
high catalytic efficiency. A gate-like structure in the
substrate-binding pocket may be an underlying factor for enzymes
catalyzing hydrophobic chemicals and thereby regulating their substrate
and/or product specificities.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The abbreviations used are:
PAPS, phosphoadenosine 5'-phosphosulfate;
E2, estradiol;
EST, estrogen
sulfotransferase;
DHEA, dehydroepiandrosterone;
HST, hydroxysteroid
sulfotransferase;
AD, androstenediol;
PREG, pregnenolone.
Substrate Gating Confers Steroid Specificity to Estrogen
Sulfotransferase*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxyl group of the
DHEA molecule is excluded from the catalytic site of EST through steric
hindrance of Tyr-81 with the C-19 methyl group of DHEA. Thus, this
stricture-like gating caused by steric hindrance appears to be a
structural principle for conferring estrogen specificity to EST.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxyl group is directed outward near the pocket
entrance. Vertical sectioning of the pocket has revealed a gate-like
structure that positions the E2 molecule. Key residues in this region
were mutated in order to examine whether they act as a gate in
determining the substrate specificity of EST. EST and its mutants were
expressed in Escherichia coli cells, purified, and used to
determine selectively their Km and
kcat values using E2, DHEA, and androstenediol
as substrates. We herein describe experimental considerations that lead
us to propose that tyrosine at position 81 is the key residue that
confers substrate specificity of EST for E2 over DHEA.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxyl group (section I). On
section II, Phe-24, Cys-84, Ile-146, and Tyr-149 reside near the
B/C-rings of the E2 molecule, whereas the side chains of Phe-24 and
Cys-84 are directed toward the C-18 methyl group. Residues Tyr-81,
Phe-142, and Tyr-240 are located around the A-ring of the E2 molecule
on section III, with the side chains of Tyr-81 and Phe-142 forming the
narrowest channel of the pocket (Fig. 1). Many of these residues were
mutated to examine their role in determining the substrate specificity
of EST.

View larger version (44K):
[in a new window]
Fig. 1.
Substrate binding pocket of EST displaying
residues that have been mutated in this study. Residues in
cyan belong to section I; residues in yellow
belong to section II, and those in magenta correspond to
section III. Sections I, II, and III are labeled based on residues that
surround the region D-, B/C-, and A-rings of E2, respectively. This
figure was created using Molscript (24).
-hydroxyl group essentially retained wild-type EST
activity. Mutation of Ser-148 to Ala displayed the most noticeable
decrease in activity (5-fold). None of these mutant enzymes increased
DHEA sulfotransferase activity. Because of its close proximity to the
C-18 methyl group, Phe-24 on section II was mutated to a smaller amino
acid Ala, whereas Cys-84 was mutated to a larger amino acid to fill the
space between its side chain and the C-18 methyl group. These mutants
(F24A, C84F, and C84Y), however, exhibited substrate specificity
similar to that of wild-type EST. Mutations of the other residues in
section II (Ile-146 and Tyr-149 that sandwich the C-ring from the
opposite side of the pocket) displayed as high E2 sulfotransferase
activity and as low DHEA sulfotransferase activity as did wild-type
EST. The most profound increase of DHEA activity occurred with a Tyr-81 mutant in section III; the Y81A mutant exhibited approximately 8-fold
higher DHEA sulfotransferase activity but decreased E2 sulfotransferase
activity by 3-fold (Table II). On the
other hand, the mutation of Phe-142 to Leu (F142L) decreased E2
activity 30-fold but did not confer activity toward DHEA. In addition,
mutations of tyrosine at position 240 did not affect the activities of
wild-type EST.
Initial screening of substrate-binding residue mutants
Kinetic analysis of the Tyr-81 and/or Phe-142 mutants
1 × 103/nM, respectively, whereas those for DHEA
were the 1 µM and 1 s
1 × 103/nM, respectively. Decreasing the side chain
size by substituting Tyr-81 with Phe, Leu, and Ala, respectively,
increased the Km(E2) values up to
10-fold. The kcat(E2) values for these mutants,
on the other hand, remained relatively constant, although Y81L
decreased kcat(E2) about 2.5-fold. Removing the
hydroxyl group from Tyr-81 by substituting it with Phe resulted in more
than 10-fold higher kcat(DHEA) for EST with
Km(DHEA) only 2.5-fold lower. Placing
Leu at position 81 (Y81L) resulted in the high
kcat(DHEA) and
Km(DHEA) values similar to those
observed with Y81F. The kcat(DHEA) of Y81A was
35-fold higher than that of wild-type EST, with both having similar
Km(DHEA) values. These results are
consistent with the hypothesis that as the size of residue 81 becomes
smaller, EST acquires higher DHEA and lower E2 sulfotransferase
activities. The highest DHEA sulfotransferase activity, however, is
achieved with the Y81L mutant. Moreover, kcat is
the primary factor for altering DHEA sulfotransferase activity, whereas
Km defines mainly E2 sulfotransferase activity. The
kcat(DHEA) and
Km(DHEA) values of Y81L were practically
identical to those of wild-type HST. As a result, the catalytic power
(Km(DHEA)/kcat(DHEA) ratio) of EST to sulfate DHEA can be strengthened to levels equal to
that for HST by a single amino acid mutation at position 81.
Kinetic parameters for androstenediol sulfotransferase activity
2 of Tyr-81 (Fig.
2). Based on a characteristic alteration of Km(E2) with mutagenesis of Tyr-81 and
Phe-142, the gate appears to determine the binding affinity for E2 to
EST. Placing a smaller residue at position 81 not only decreases E2
sulfotransferase activity but also increases DHEA sulfotransferase
activity. Mutation of Phe-142 is more destructive, resulting in a
profound decrease of both E2 and DHEA sulfotransferase activities of
this enzyme, consistent with the fact that Phe-142 is conserved in all
cytosolic sulfotransferases. Thus, the Tyr-81/Phe-142 gate is a
structural factor that determines the estrogen specificity of EST.

View larger version (44K):
[in a new window]
Fig. 2.
Superposition of DHEA to E2 in the EST
substrate gate. E2 is in green, DHEA in
blue, and the gate residues Tyr-81 and Phe-142 in
magenta. The van der Waals surfaces are displayed for E2,
Tyr-81, and Phe-142. The possible clashing contact that would exist if
DHEA were forced to bind to wild type EST (between C-19 of DHEA and
C-
2 of Tyr-81) is represented by a cyan line. This figure
was created using Molscript (24).
2) of the phenol ring of Tyr-81 but not with the phenolic
hydroxyl at the 3-position (3.85 Å). Paradoxically, our present
site-directed mutagenesis of Tyr-81 has suggested that the C-19 methyl
group may conflict sterically with the phenol group. This apparent
paradox might be explained if DHEA does not bind exactly in the same
manner as the E2 molecule pictured in Fig. 1 and thus may actually have
a steric interaction with the phenol group. Alternatively, the
structural orientation of the Phe side chain with respect to the Tyr at
this position may differ, thus allowing the Y81F mutant to accommodate
DHEA. Nevertheless, it should be reiterated that placing a smaller
amino acid at position 81 can widen the Tyr-81/Phe-142 gate, resulting
in an increase of DHEA sulfotransferase activity in EST.
![]()
FOOTNOTES
To whom correspondence should be addressed: Laboratory of
Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709. Tel.: 919-541-2404; Fax:
919-541-0696; E-mail: negishi@niehs.nih.gov.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Hobkirk, R.
(1993)
Trends Endocrinol. Metab.
4,
69-73
2.
Evans, T. R.,
Rowlands, M. G.,
Law, M.,
and Coombes, R. C.
(1994)
Br. J. Cancer
69,
555-561[Medline]
[Order article via Infotrieve]
3.
Utsumi, T.,
Yoshimura, N.,
Takeuchi, S.,
Ando, J.,
Maruta, M.,
Meada, K.,
and Harada, N.
(1999)
Cancer Res.
59,
377-381 4.
Ahmed, S.,
James, K.,
Sampson, L.,
and Mastri, C.
(1999)
Biochem. Biophys. Res. Commun.
254,
811-815[Medline]
[Order article via Infotrieve]
5.
Selcer, K. W.,
Jagannathan, S.,
Rhodes, M. E.,
and Li, P.-K.
(1996)
J. Steroid Biochem. Mol. Biol.
59,
83-91[CrossRef][Medline]
[Order article via Infotrieve]
6.
Weinshilboum, R. M.,
Otterness, D. M.,
Aksoy, I. A.,
Wood, T. C.,
Her, C.,
and Raftogianis, R. B.
(1997)
FASEB J.
11,
3-14[Abstract]
7.
Varin, L.,
Marsolais, F.,
Richard, M.,
and Rouleau, M.
(1997)
FASEB J.
11,
517-525[Abstract]
8.
Brix, L. A.,
Duggleby, R. G.,
Gaedigk, A.,
and McManus, E.
(1999)
Biochem. J.
337,
337-343
9.
Dajani, R.,
Hood, A. M.,
and Coughtrie, M. H.
(1998)
Mol. Pharmacol.
54,
942-948 10.
Song, W.-C.,
Moore, R.,
McLachlan, J. A.,
and Negishi, M.
(1995)
Endocrinology
136,
2477-2484[Abstract]
11.
Kakuta, Y.,
Pedersen, L. C.,
Chea, K.,
Song, W.-C.,
Lablanc, D.,
London, R.,
Carter, C. W.,
and Negishi, M.
(1998)
Biochem. Pharmacol.
55,
313-317[CrossRef][Medline]
[Order article via Infotrieve]
12.
Kakuta, Y.,
Pedersen, L. G.,
Carter, C. W.,
Negishi, M.,
and Pedersen, L. C.
(1997)
Nat. Struct. Biol.
4,
904-908[CrossRef][Medline]
[Order article via Infotrieve]
13.
Kakuta, Y.,
Petrotchenko, E. V.,
Pedersen, L. C.,
and Negishi, M.
(1998)
J. Biol. Chem.
273,
27325-27330 14.
Duffel, M. W.,
and Jakoby, W. B.
(1981)
J. Biol. Chem.
256,
11123-11127 15.
Zhang, H.,
Varmalova, O.,
Vargas, F. M.,
Falany, C. N.,
and Leyh, T. S.
(1998)
J. Biol. Chem.
273,
10888-10892 16.
Kakuta, Y.,
Pedersen, L. G.,
Pedersen, L. C.,
and Negishi, M.
(1998)
Trends Biochem. Sci.
23,
129-130[CrossRef][Medline]
[Order article via Infotrieve]
17.
Sueyoshi, T.,
Kakuta, Y.,
Pedersen, L. C.,
Wall, F. E.,
Pedersen, L. G.,
and Negishi, M.
(1998)
FEBS Lett.
433,
211-214[CrossRef][Medline]
[Order article via Infotrieve]
18.
Kakuta, Y.,
Sueyoshi, T.,
Negishi, M.,
and Pedersen, L. C.
(1999)
J. Biol. Chem.
274,
10673-10676 19.
Negishi, M.,
Uno, T.,
Darden, T. A.,
Sueyoshi, T.,
and Pedersen, L. G.
(1996)
FASEB J.
10,
683-689[Abstract]
20.
Lindberg, R.,
and Negishi, M.
(1989)
Nature
338,
632-634
21.
Graham-Lorence, S.,
Truan, G.,
Peterson, J. A.,
Falck, J. R.,
Wei, S.,
Helvig, C.,
and Capdevila, J. H.
(1997)
J. Biol. Chem.
272,
1127-1135 22.
Sloane, D. L.,
Leung, R.,
Craik, C. S.,
and Sigai, E.
(1991)
Nature
354,
149-152[CrossRef][Medline]
[Order article via Infotrieve]
23.
Wyckoff, T. J. O.,
Lin, S.,
Cotter, R. J.,
Dotson, G. D.,
and Rartz, C. R. H.
(1998)
J. Biol. Chem.
273,
32369-32372 24.
Kraulis, P. J.
(1991)
J. Appl. Crystallogra.
24,
946-950[CrossRef]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
R. Kapoor and J. J. Sheng Transfection of Human Prostate Cancer CA-HPV-10 Cells with Cytosolic Sulfotransferase SULT1E1 Affects Estrogen Signaling and Gene Transcription Drug Metab. Dispos., February 1, 2008; 36(2): 316 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Sheng, A. Saxena, and M. W. Duffel INFLUENCE OF PHENYLALANINES 77 AND 138 ON THE STEREOSPECIFICITY OF ARYL SULFOTRANSFERASE IV Drug Metab. Dispos., May 1, 2004; 32(5): 559 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Shi and S.-X. Lin Cofactor Hydrogen Bonding onto the Protein Main Chain Is Conserved in the Short Chain Dehydrogenase/Reductase Family and Contributes to Nicotinamide Orientation J. Biol. Chem., April 16, 2004; 279(16): 16778 - 16785. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Chen and X. Chen Arginine Residues in the Active Site of Human Phenol Sulfotransferase (SULT1A1) J. Biol. Chem., September 19, 2003; 278(38): 36358 - 36364. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Strott Sulfonation and Molecular Action Endocr. Rev., October 1, 2002; 23(5): 703 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-C. Song and M. H. Melner Editorial: Steroid Transformation Enzymes as Critical Regulators of Steroid Action in Vivo Endocrinology, May 1, 2000; 141(5): 1587 - 1589. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |